Impact of recA on levofloxacin exposure-related resistance development

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4262-4268

  Singh, Renu ^a   Ledesma, Kimberly R ^a   Chang, Kai Tai ^a   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; PLACEBO; QUINOLONE;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EXPOSURE; ESCHERICHIA COLI; FEMALE; GENE DELETION; GENETIC VARIABILITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECA GENE; STAPHYLOCOCCUS AUREUS; WILD TYPE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; MUTATION; OFLOXACIN; REC A RECOMBINASES; STAPHYLOCOCCUS AUREUS;

EID: 77957371845     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00168-10     Document Type: Article

References (20)

1. Almahmoud, I., E. Kay, D. Schneider, and M. Maurin. 2009. Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila. J. Antimicrob. Chemother. 64:284-293.
2. Chen, J. Y., L. K. Siu, Y. H. Chen, P. L. Lu, M. Ho, and C. F. Peng. 2001. Molecular epidemiology and mutations at gyrA and parC genes of cipro-floxacin-resistant Escherichia coli isolates from a Taiwan medical center. Microb. Drug Resist. 7:47-53.
3. Chuanchuen, R., W. Wannaprasat, K. Ajariyakhajorn, and H. P. Schweizer. 2008. Role of the MexXY multidrug efflux pump in moderate aminoglycoside resistance in Pseudomonas aeruginosa isolates from Pseudomonas mastitis. Microbiol. Immunol. 52:392-398.
4. Cirz, R. T., J. K. Chin, D. R. Andes, V. de Crecy-Lagard, W. A. Craig, and F. E. Romesberg. 2005. Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol. 3:e176.
5. Cirz, R. T., M. B. Jones, N. A. Gingles, T. D. Minogue, B. Jarrahi, S. N. Peterson, and F. E. Romesberg. 2007. Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin. J. Bacteriol. 189: 531-539.
6. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing: 17th informational supplement. CLSI document M100-S17. CLSI, Wayne, PA.
7. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II user's guide: pharmacokinetic/ pharmacodynamic systems analysis software. Biomedical simulations resource. University of Southern California, Los Angeles, LA.
8. Erill, I., S. Campoy, and J. Barbe. 2007. Aeons of distress: an evolutionary perspective on the bacterial SOS response. FEMS Microbiol. Rev. 31:637-656.
9. Lopez, E., M. Elez, I. Matic, and J. Blazquez. 2007. Antibiotic-mediated recombination: ciprofloxacin stimulates SOS-independent recombination of divergent sequences in Escherichia coli. Mol. Microbiol. 64:83-93.
10. McDougal, L. K., C. D. Steward, G. E. Killgore, J. M. Chaitram, S. K. McAllister, and F. C. Tenover. 2003. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41:5113-5120.
11. Mesak, L. R., V. Miao, and J. Davies. 2008. Effects of subinhibitory concentrations of antibiotics on SOS and DNA repair gene expression in Staphylococcus aureus. Antimicrob. Agents Chemother. 52:3394-3397.
12. Morgan-Linnell, S. K., L. Becnel Boyd, D. Steffen, and L. Zechiedrich. 2009. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 53:235-241.
13. Oteo, J., A. Delgado-Iribarren, D. Vega, V. Bautista, M. C. Rodriguez, M. Velasco, J. M. Saavedra, M. Perez-Vazquez, S. Garcia-Cobos, L. Martinez-Martinez, and J. Campos. 2008. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int. J. Antimicrob. Agents 32:534-537.
14. Pea, F., E. Di Qual, A. Cusenza, L. Brollo, M. Baldassarre, and M. Furlanut. 2003. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin. Pharmacokinet. 42:589-598.
15. Perez-Capilla, T., M. R. Baquero, J. M. Gomez-Gomez, A. Ionel, S. Martin, and J. Blazquez. 2005. SOS-independent induction of dinB transcription by beta-lactam-mediated inhibition of cell wall synthesis in Escherichia coli. J. Bacteriol. 187:1515-1518. (Pubitemid 40299476)
16. Riesenfeld, C., M. Everett, L. J. Piddock, and B. G. Hall. 1997. Adaptive mutations produce resistance to ciprofloxacin. Antimicrob. Agents Chemother. 41:2059-2060.
17. Singh, R., K. R. Ledesma, K. T. Chang, J. G. Hou, R. A. Prince, and V. H. Tam. 2009. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model. J. Antimicrob. Chemother. 64:556-562.
18. Tam, V. H., A. Louie, M. R. Deziel, W. Liu, and G. L. Drusano. 2007. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob. Agents Chemother. 51:744-747.
19. Tam, V. H., A. Louie, T. R. Fritsche, M. Deziel, W. Liu, D. L. Brown, L. Deshpande, R. Leary, R. N. Jones, and G. L. Drusano. 2007. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J. Infect. Dis. 195:1818-1827.
20. Von Groll, A., A. Martin, P. Jureen, S. Hoffner, P. Vandamme, F. Portaels, J. C. Palomino, and P. A. da Silva. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob. Agents Chemother. 53:4498-4500.